Wbp2-flox 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Wbp2-flox 基因敲除小鼠

产品编号

S-CKO-06662

品系全称

C57BL/6JCya-Wbp2em1flox/Cya

品系背景

C57BL/6JCya

品系编号

CKOCMP-22378-Wbp2-B6J-VA

品系状态

使用本品系发表的文献需注明: Wbp2-flox 基因敲除小鼠 mice (Strain S-CKO-06662) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量
cKO小鼠库模型

基本信息

基因研究概述

质控标准

基因
基因全称
WW domain binding protein 2
基因别称
-
染色体号
Chr 11 (Mouse)
转录本 ID
NCBI: NM_016852 | Ensembl: ENSMUST00000074628
修饰方式
条件性基因敲除
靶向范围
Exon 2
敲除长度
~0.9 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:104709Mice homozygous for a null allele show progressive high-frequency hearing loss, raised auditory brainstem response (ABR) thresholds, reduced ABR amplitudes, swelling of afferent terminals, inner hair cell synapse defects, and altered expression of AMPA receptor subunits and post-synaptic proteins.
WW domain binding protein 2(WBP2)是一种重要的蛋白质,在多种生物学过程中发挥着关键作用。WBP2作为一种适配蛋白,与多种WW结构域蛋白相互作用,参与调控信号通路、细胞迁移、增殖和凋亡等过程。在乳腺癌、胃癌等多种癌症中,WBP2表达上调,与肿瘤的发生发展密切相关。

研究表明,WBP2在乳腺癌的发生发展中起着重要作用。WBP2可以与雌激素受体(ER)和孕酮受体(PR)相互作用,促进其转录活性,从而影响乳腺癌的发生和发展[1,3]。此外,WBP2还可以与WW结构域蛋白YAP和TAZ相互作用,促进乳腺癌细胞的迁移和侵袭[3]。在HER2阳性乳腺癌中,WBP2与HER2共扩增,并与其表达水平呈正相关,提示WBP2可能参与了HER2阳性乳腺癌的发生和发展[7]。WBP2还可以与LATS2相互作用,抑制其磷酸化,进而激活YAP/TEAD信号通路,促进乳腺癌细胞的迁移[6]。此外,WBP2还可以通过调控MDR1的转录,增加乳腺癌细胞对化疗药物的耐药性[5]。

在胃癌中,WBP2表达上调,与胃癌的发生发展和预后密切相关。WBP2可以与LATS2相互作用,抑制其磷酸化,进而激活YAP/TEAD信号通路,促进胃癌细胞的迁移[6]。此外,WBP2还可以通过上调EGFR/PI3K/Akt信号通路,促进胃癌细胞的增殖和凋亡[4]。

除了在肿瘤中的作用,WBP2还参与调节听觉功能。WBP2可以与雌激素受体α(ESR1)和孕酮受体(PGR)相互作用,促进其转录活性,从而影响听觉功能[2]。WBP2的缺失会导致听力下降,这表明WBP2在听觉系统中发挥着重要作用。

WBP2是一种重要的蛋白质,在多种生物学过程中发挥着关键作用。WBP2在肿瘤的发生发展、听觉功能等方面发挥着重要作用。深入研究WBP2的功能和调控机制,对于肿瘤的治疗和预防具有重要意义。

参考文献:
1. Liu, Yan, He, Enping, Zhang, Yanling, Zeng, Youqing, Leng, Ping. . WW domain binding protein 2 (WBP2) as an oncogene in breast cancer: mechanisms and therapeutic prospects-a narrative review. In Gland surgery, 11, 1984-2002. doi:10.21037/gs-22-716. https://pubmed.ncbi.nlm.nih.gov/36654949/
2. Buniello, Annalisa, Ingham, Neil J, Lewis, Morag A, Marcotti, Walter, Steel, Karen P. . Wbp2 is required for normal glutamatergic synapses in the cochlea and is crucial for hearing. In EMBO molecular medicine, 8, 191-207. doi:10.15252/emmm.201505523. https://pubmed.ncbi.nlm.nih.gov/26881968/
3. Chen, Shuai, Wang, Han, Huang, Yu-Fan, Tzeng, Chi-Meng, Zhang, Zhi-Ming. 2017. WW domain-binding protein 2: an adaptor protein closely linked to the development of breast cancer. In Molecular cancer, 16, 128. doi:10.1186/s12943-017-0693-9. https://pubmed.ncbi.nlm.nih.gov/28724435/
4. Song, Hongming, Wu, Tianqi, Xie, Dan, Hu, Jiashu, Fang, Lin. 2018. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer. In Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 48, 1968-1982. doi:10.1159/000492520. https://pubmed.ncbi.nlm.nih.gov/30092563/
5. Chen, Shuai, Wang, Han, Li, Zhi, Tzeng, Chi-Meng, Zhang, Zhi-Ming. 2018. Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription. In British journal of cancer, 119, 182-192. doi:10.1038/s41416-018-0119-5. https://pubmed.ncbi.nlm.nih.gov/29937544/
6. Hum, Melissa, Tan, Hock Jin, Yang, Yixuan, Teh, Ming, Lim, Yoon Pin. . WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway. In FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35, e21290. doi:10.1096/fj.202000393R. https://pubmed.ncbi.nlm.nih.gov/33475198/
7. Kang, Shin-Ae, Guan, Jye Swei, Tan, Hock Jin, Lee, Soo Chin, Lim, Yoon Pin. 2018. Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study. In Clinical cancer research : an official journal of the American Association for Cancer Research, 25, 2588-2600. doi:10.1158/1078-0432.CCR-18-3228. https://pubmed.ncbi.nlm.nih.gov/30593516/